CompletedPhase 1NCT05132907

Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
HDT Bio
Principal Investigator
Steven G Reed, Ph.D
HDT Bio
Intervention
HDT-301(biological)
Enrollment
48 target
Eligibility
18-65 years · All sexes
Timeline
20222024

Study locations (1)

Collaborators

Rainier Clinical Research Center · C3 Research Associates

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05132907 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials